Jetcraft First to Offer Microshield 360 Antimicrobial Treatment by F/LIST
20.7.2020 11:00:00 EEST | Business Wire | Press release
Jetcraft, the world leader in business jet sales and acquisitions, is the launch customer for interiors specialist F/LIST’s Microshield 360 treatment program, which protects against SARS-CoV-2* and other pathogens that may otherwise live on cabin surfaces.
Additionally, Jetcraft is the first aircraft dealer using MicroShield 360. The coating system is available for all in-service aircraft purchased through the company, and will be applied to all eligible aircraft within Jetcraft’s owned inventory, beginning July 14.
Chad Anderson, president at Jetcraft, says: “MicroShield 360 is one of many ways we are expanding our offering to meet clients’ needs during Covid-19. We are pleased to be the first aircraft dealer implementing the treatment, so buyers can be confident their health is protected when purchasing directly from Jetcraft.
“Our first two jets, a Bombardier Challenger 604 and Global 5000, were treated by F/LIST on July 14. I was highly impressed by the speed of the application, which only took two hours from start to finish for a whole year of protection.”
MicroShield 360 is an antimicrobial coating system which is colorless, odorless and safe for all aircraft interiors. Owners can be reassured that it is eco-friendly, non-toxic and hypoallergenic, and won’t cause any deterioration to their aircraft cabin.
The interior application takes place in two parts: an initial disinfectant to sterilize the cabin, followed by the application of MicroShield 360, which forms a barrier of nanoscopic spikes. The spikes physically destroy germs by piercing the cell membranes, preventing them from adhering to and contaminating a surface.
An electrostatic sprayer is used to apply MicroShield 360, generating a molecular bond with the cabin surface which is equal to 40x the pull of gravity. As a result, the system is extremely abrasion resistant. Combined with regular cleaning, the treatment will ensure all surfaces are effectively self-disinfecting for 12+ months.
Sean Johnson, CEO, F/LIST Canada, adds: “In the present climate, it pays to be fastidious about your health and the cleanliness of your environment, particularly whilst traveling. With F/List partnering with Jetcraft we can bring MicroShield 360 directly to new aircraft owners, underlining how safe, controlled and comfortable travel can be when flying privately. F/List has long been known for innovative technologies that upgrade the cabin experience, and MicroShield 360 falls perfectly into that category.”
All Microshield 360 treatments are subject to Jetcraft approval. Some exclusions apply.
*SARS-CoV-2 is the virus that causes Covid-19.
ENDS
About Jetcraft
Jetcraft is the leader in international aircraft sales, marketing and ownership strategies, managing and maintaining over 20 regional offices globally. The company’s unparalleled success over more than 55 years in business aviation has earned it a world-class reputation, along with an exceptional customer base, a wide network of connections and one of the largest inventories within the industry.
For more information, please visit www.jetcraft.com
About F/LIST
F/LIST is a worldwide provider of interiors for business jets, yachts and residences, and engages more than 900 employees at eight locations in Europe, the Middle East and the Americas. Passion, reliability and a visionary spirit determine every step of this Austrian family-run business.
For more information, please visit https://f-list.at/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005038/en/
Contact information
8020 Communications.
Michaela Wilkins
Email: jetcraft@8020comms.com
Telephone: +44 (0)1483 447380
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a
Zayed Sustainability Prize Closes 2027 Submissions with Strong Global Participation13.7.2026 12:48:00 EEST | Press release
The Zayed Sustainability Prize, the UAE’s pioneering award for innovative solutions to global challenges, has officially closed submissions for its 2027 awards cycle, receiving an unprecedented 10,233 entries from 177 countries across its six categories of Health, Food, Energy, Water, Climate Action and Global High Schools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713519403/en/ Zayed Sustainability Prize Closes 2027 Submissions with Strong Global Participation (Photo: AETOSWire) Now in its 18th year, the Prize continues to attract a diverse and growing pool of small and medium-sized enterprises, nonprofit organisations and high schools developing solutions that improve lives, particularly in vulnerable and underserved communities. This year’s submissions point to a growing emphasis on resilience, adaptability and systems-level impact. Across regions, applicants are addressing complex global challenges through practi
Ant Group Open-Sources SingGuard-NSFA to Establish New Security Paradigms for Autonomous AI Agents13.7.2026 12:01:00 EEST | Press release
Ant Group’s AI Security Lab today announced the open-source release of SingGuard-NSFA, a specialized security guardrail framework designed specifically for autonomous AI agents. The framework secures agentic AI systems against operational threats like prompt injection, addressing critical vulnerabilities as AI transitions from passive content generation to active, autonomous execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712722454/en/ As AI agents rapidly move from research labs to business scenarios, the security landscape has fundamentally shifted. The explosive global adoption of open-source agent frameworks like OpenClaw, celebrated for their "one-click deployment" and "full-stack autonomy", has simultaneously exposed significant operational risks, including permission escalation and prompt injection. Industry frameworks, including the OWASP (Open Web Application Security Project) Top 10 for Agentic Applica
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types13.7.2026 11:00:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris. Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability to prevent or reduce the frequency of bleeding episodes. Latarcibart is in pivotal Phase 3 development for patients with VWD, the most common inherited bleeding disorder. If approved, latarcibart has the potential to be the first, once monthly subcutaneous prophylactic therapy for patients with VWD, offering an important alternative to the frequent intravenous infusions of replacement factor concentrates commonly used in the prophylactic setting today. Gi
Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™13.7.2026 11:00:00 EEST | Press release
Demand for technology services in Europe continued to accelerate in the second quarter, as the region increasingly turns to managed services to reduce costs and cloud services to meet AI objectives, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) soared 46 percent—its largest growth in eight years—to US $13.0 billion. The latest quarter adds to a string of three straight quarters in which growth has averaged 33 percent. “Europe has become the fastest-growing region for technology services, fueled not only by an increasing demand for AI, but for managed services, which acts as a cost-savings lever to help fund AI ambitions and continued digital
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom